Back to results
US 12,715,858 B2Granted
Pyridazinone compounds
AssigneeInventisbio Co., Ltd.
InventorsXing Dai, Yanqin Liu, Yueheng Jiang
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds, in particular, Compound 1, and compositions useful for treating or preventing diseases or disorders that are modulated by thyroid hormone receptor agonists, such as non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD).
Claims7
The Compound 1,
- which is in a crystalline form,
- wherein the crystalline form is:
- i) Form I of Compound 1, characterized by (1) an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks:
- 10.8, 12.2, 12.4, 14.0, 17.1, 17.8, 22.6, 23.6, 24.6, 25.4, 26.0, and 28.8, degrees 2 theta, ±0.2°;
- (2) an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks:
- 10.8, 12.2, 12.4, 14.0, 17.1, 17.4, 17.8, 20.1, 20.4, 22.6, 23.6, 24.6, 25.0, 25.4, 26.0, 28.8, 30.0, and 33.1 degrees 2 theta, ±0.2°;
- (3) an XRPD pattern substantially the same as shown in FIG. 1A or Table 1;
- (4) a Differential Scanning Calorimetry (DSC) pattern substantially the same as shown in FIG. 1B;
- or any combination thereof;
- or
- ii) Form II of Compound 1, characterized by (1) an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks:
- 16.7, 17.6, 18.9, 19.8, 20.1, 20.7, 22.5, 22.7, 23.7, 24.0, and 26.5, degrees 2 theta, ±0.2°;
- (2) an X-ray powder diffraction (XRPD) pattern having one or more of the following peaks:
- 9.9, 10.8, 16.7, 17.6, 18.9, 19.8, 20.1, 20.7, 21.2, 21.6, 22.3, 22.5, 22.7, 23.7, 24.0, 24.8, 26.5, 26.7, 28.1, 29.7, and 30.7, degrees 2 theta, ±0.2°;
- (3) an XRPD pattern substantially the same as shown in FIG. 2A or Table 2;
- (4) a Differential Scanning Calorimetry (DSC) pattern substantially the same as shown in FIG. 2B;
- or any combination thereof.
14 more elements
Dependencies are inferred from the claim text.